Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 295
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT07728097 | A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS | ||
| NCT05974293 | A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders | ||
| NCT01696084 | Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia | ||
| NCT02565108 | A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol | ||
| NCT02348619 | "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" | ||
| NCT01888120 | Patient Registry of Intrathecal Ziconotide Management(PRIZM) | ||
| NCT07282587 | Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | ||
| NCT00713323 | A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain. | ||
| NCT05485831 | Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY | ||
| NCT04592159 | Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder | ||
| NCT01769170 | A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients | ||
| NCT03954106 | A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity | ||
| NCT04984278 | Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis | ||
| NCT03339297 | An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) | ||
| NCT06261450 | Effect of CBD on the Brain | ||
| NCT03865589 | Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome | ||
| NCT00594256 | Sodium Oxybate in Schizophrenia With Insomnia | ||
| NCT01812603 | A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma | ||
| NCT00457951 | A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD | ||
| NCT07533942 | A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | ||
| NCT02091375 | Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) | ||
| NCT02806895 | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA | ||
| NCT03929666 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | ||
| NCT03406702 | CX-8998 for Absence Seizures | ||
| NCT00710424 | A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy | ||
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | ||
| NCT01323569 | Abuse Potential of Sativex | ||
| NCT01080820 | A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers | ||
| NCT01322139 | Sativex Thorough QT/QTc Study | ||
| NCT06961266 | A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1 | ||
| NCT04721691 | Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES). | ||
| NCT07290985 | AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas | ||
| NCT04269213 | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old | ||
| NCT03555955 | A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 | ||
| NCT02953548 | Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7) | ||
| NCT01424566 | A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer | ||
| NCT00097708 | Experimental Medication For the Treatment of Generalized Anxiety Disorder | ||
| NCT07156435 | Vyxeos® With Clofarabine for Pediatric AML | ||
| NCT04571645 | Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia | ||
| NCT07102381 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | ||
| NCT00358501 | Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients | ||
| NCT07153055 | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer | ||
| NCT04652115 | Defibrotide for the Treatment of Severe COVID-19 | ||
| NCT02806908 | Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy | ||
| NCT03526926 | A Post-Marketing Observational Study of VYXEOS™ | ||
| NCT02660255 | Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy | ||
| NCT06282575 | Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | ||
| NCT02073474 | An Observational Post-Marketing Safety Registry of Sativex® | ||
| NCT05734066 | Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | ||
| NCT05260528 | CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics |
